AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03218709 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: High-dose multi-vitamins with minerals
Description: The high-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.37mg,vitamin C 0.27mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
Study NCT00402155 — intervention group
Intervention type: BEHAVIORAL
Intervention: Stress on visual discomfort
Description: Effects of visual discomfort are measured by contrast sensitivity, ERGs, and accommodative stability.
Study NCT03218709 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low-dose multi-vitamins with minerals
Description: The low-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.20mg,vitamin C 0.50mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
Study NCT03218709 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hypouricemic tablets
Description: The hypouricemic tablets contained skipjack,salvia and rosemary extract.
Study NCT03218709 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablets contained maltodextrin and tartrazine.
Study NCT03532841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet
Description: Group I will receive an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet one hour before the procedure.
Study NCT03532841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo tablet of the same shape,color and taste will be given in the placebo arm
Study NCT02917850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isokinetic hip flexors strengthening
Description: Isokinetic excentric strengthening of paretic hip flexors, 3/w during 6 weeks, in addition to conventional rehabilitation 7/w.
Study NCT02917850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Conventional rehabilitation 10/w during 6 weeks
Study NCT03840174 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160
Description: V160 administered as a 0.5 mL (100 Units) IM injection containing 225 mcg aluminum phosphate adjuvant (APA)
Study NCT03840174 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution (0.9% sodium chloride \[NaCl\] administered as a 0.5 mL IM injection
Study NCT01857856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: eplerenone (inspra; pfizer) one tablet (50mg standard dosis; 25mg reduced dosis) per day
Study NCT02973061 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: All participants families will fulfill a periodic questionnaire regarding attention, behaviour.
Study NCT02527161 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ShapeMatch Cutting Guides with Triathlon
Description: All participants will undergo medical imaging assessment using Magnetic Resonance Imaging (MRI) of the affected lower limb.These images will be used to manufacture the patient-specific cutting guides for preparation of the bones prior to implantation of the total knee replacement (Pre-operatively). Patients will undergo primary total knee arthroplasty with the Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA) using the Shapematch cutting guides to guide the bone resection. Patients will follow the standard postoperative rehabilitation program established by the investigator at each site.
Study NCT04099095 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Appointment
Description: The participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant
Study NCT04099095 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Appointment
Description: After a period of delay (control) the participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant
Study NCT01056029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-202
Description: Thapsigargin is Pro-drug chemotherapy which will be administered by intravenous infusion over 1 hour on Days, 1, 2 and 3 of each 28 day cycle
Study NCT02248701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: Subjects receive testosterone (125 mg/week) by intramuscular injection
Study NCT02248701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Subjects receive finasteride (5 mg/day) orally
Study NCT02248701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Subjects receive placebo (weekly) by intramuscular injection
Study NCT02248701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Subjects receive placebo pill (daily) orally
Study NCT00986830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FinESS Sinus Treatment
Study NCT02702804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: High Intensity Interval Training
Study NCT04794309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit training exercise
Description: circuit training exercise start with 5 minutes of warming-up then followed by a 30-minute conditioning protocol formed 20 minutes of aerobic exercise and 10 minutes of resisted exercise. The cool-down period is doing in form of walking on a treadmill in low intensity for 5 minutes.~Aerobic exercise will be performed on an electronically-braked cycle ergometer (Quinton Excalibur, QuintonInstrument Company, Bothell, WA). resistance exercise (RT) in the form of eight different exercises will be performed during each workout: military press, leg extension, bench press, standing leg curl (ankle weights), lateral pull-down, dumbbell triceps push-down, dumbbell seated biceps curl, and sit-ups (abdominal curls).~The participant will do 10 minutes for Aerobic exercise followed by 10 minutes of resistance exercise then 10 minutes for Aerobic exercise. This cycle training will perform five days per week for eight weeks.
Study NCT04794309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Healthy high Fiber diet
Description: The diet will be tailor-made for the individual for the body type and obesity in consultation with the nutritionist.
Study NCT04794309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Healthy high Fiber diet
Description: The diet will be tailor-made for the individual for the body type and obesity in consultation with the nutritionist.
Study NCT00731068 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGF
Description: injection of 6cc into injured area of tendon
Study NCT00731068 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: injection of 6 cc of saline into injured area
Study NCT03328117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Over-encapsulated 100 mg imatinib mesilate tablets
Study NCT03328117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo oral capsule
Study NCT03143309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Brief introductory session, pedometer instruction, daily pedometer use, and health messages delivered via WhatsApp 2-3 times per week.
Study NCT03143309 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Non-health related messages delivered via WhatsApp 2-3 times per week.
Study NCT03861949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 cmH2O CPAP
Study NCT03861949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: head-up position
Study NCT00964184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT01785433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiriva® Respimat® 5 mcg/day
Study NCT01002625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845 / matched placebo
Description: PF-04457845 4 mg tablet once daily / matched placebo
Study NCT01474330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 0.5-mg, 1-mg, or 2-mg capsule administered once daily for 5 days under fasted conditions
Study NCT01474330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule
Study NCT01956409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FCH
Study NCT01956409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnevist
Study NCT00500786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT006-AngQb
Study NCT00850460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statins
Description: Subjects will be randomized to continue their statin dosage or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician. Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20 mg/tab once daily by mouth.
Study NCT00850460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills will consist of lactose and will be given one capsule once daily
Study NCT04159194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Diet
Description: Players during the control trial will be instructed to maintain their normal food intake (\~55% CHO) and the type and amount of ingested food will be recorded.
Study NCT04159194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Diet
Description: The experimental diet will be administered by the investigators after M1, daily for the next 48 hours (three main meals, i.e. breakfast, lunch, and dinner, and snacks such as energy bars and raisins), and before M2 (breakfast and lunch)
Study NCT06120634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgical method
Description: After separating the preputial skin from glans and removing smegma, two artery clips were applied on the dorsal skin in the center to mark the skin to be divided. Crushing the skin for a couple of minutes, prior to incising, helps to reduce bleeding. The skin was cut about 2-3 mm short of the coronal sulcus. Similarly, 2-3 mm cuff of prepuce was circumferentially cut proximal to the corona. Using bipolar diathermy or catgut 4/0, frenular artery along with dorsal artery and vein of penis were coagulated or ligated respectively to achieve hemostasis. The skin and prepuce were approximated and sutured with catgut 4/0 at four places- ventral, dorsal, and two lateral points. Finally, a dressing with antibiotic ointment was applied to the wound.
Study NCT06120634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plastibell method
Description: The prepuce was separated all around the glans, up to the coronal sulcus, and smegma was removed. A dorsal slit in the skin was made, after crushing the skin for a couple of minutes, long enough to accommodate the passage of an appropriate-sized plastibell. Once the distal edge of the bell snugly fit at or near the coronal sulcus, a ligature was applied and tightened around the sulcus on the bell. The extra preputial skin was cut with either scissors or a surgical blade, after breaking apart and discarding the handle of the plastibell. The urethral meatus was examined and its visibility was ensured prior to returning the baby boy to his parents. The baby was kept under observation for 30 minutes in the surgical ward and re-examined to ensure there was no hematoma or bleeding.
Study NCT00475917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL844
Description: Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing.
Study NCT00475917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: once-weekly 30-minute IV infusion
Study NCT00703976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.
Study NCT00703976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
Study NCT00703976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
Study NCT02074930 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Microporation by P.L.E.A.S.E. Professional / Prick needle
Study NCT01049568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cell Phone Intervention
Description: Cell phone support, including reminders, assessment of barriers to adherence, problem solving and referrals conducted by an Adherence Facilitator.~Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization.
Study NCT01691131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise training
Description: Comparison of high intensity exercise training on land versus water.
Study NCT00703976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
Study NCT02583282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 500 mg of doxycycline will be dissolved in 50 ml of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
Study NCT02583282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Iodopovidine
Description: 20 ml of 10% betadine (Microshield, Johnson and Johnson, Solan, India) will be dissolved in 80 mL of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
Study NCT03507803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Biofeedback
Description: Feedback will appear on screen in front of participants during walking. If their foot is too inverted (determined by researcher) the object on the screen will turn red and an audio tone will be heard. If the participant corrects the foot position, the object will turn green and the audio tone will not be heard.
Study NCT01171040 — intervention group
Intervention type: OTHER
Intervention: Echocardiography, including the measurements of left atrial (LA) distensibility
Description: The LA volumes were measured at three points: 1) immediately before the mitral valve opening (maximal LV volume or Volmax); 2) at onset of the P-wave on electrocardiography (pre-atrial contraction volume or Volp); and 3) at mitral valve closure (minimal LV volume or Volmin). The LA distensibility was calculated as (Volmax - Volmin)x 100% / Volmin. The LA ejection fraction was calculated as (Volp - Volmin)x 100% / Volp. In all patients, LA volumes were indexed to body surface area (BSA).
Study NCT01145625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Minoxidil
Description: half a cap (equivalent to 1g) 5% Minoxidil Topical Foam applied to the scalp once daily, every day, for 52 weeks
Study NCT01145625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Minoxidil
Description: one ml of 2% Minoxidil Topical Solution applied to the scalp two times a day, every day, for 52 weeks
Study NCT00964184 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle modification
Study NCT01489176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson; Optison
Description: A one-time intravenous bolus of Regadenoson 400 mcg; continuous intravenous infusion of Optison of 2-4 mL/minute.
Study NCT00111501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Use Disorder
Description: Web-based psychoeducational intervention culturally-tailored to the LGBT community including a social support component
Study NCT00111501 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Web-based intervention
Description: General psychoeducational Web-based smoking cessation intervention
Study NCT02573168 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GeneSight Psychotropic (GEN)
Description: Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
Study NCT02573168 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Enhanced-GeneSight Psychotropic (E-GEN)
Description: The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
Study NCT00703976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
Study NCT00703976 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks
Study NCT00703976 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks
Study NCT04760587 — intervention group
Intervention type: BEHAVIORAL
Intervention: smart devices in adolescent weight control
Description: The study will apply mobile phone applications and smart watches to understand the relationship between weight control behaviors and weight control health outcome in adolescent.
Study NCT05783856 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiveSpo X-secret
Description: In Vietnam, LiveSpo X-secret is manufactured as a Class-A medical device product (Product declaration No.220003286/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
Study NCT05783856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl physiological saline
Description: Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 15 mL-bottle that is used for LiveSpo X-secret.
Study NCT00193973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C
Description: Idarubicin 15mg/m2 days 1, 22. Filgrastim 5mcg/kg until neutrophil recovery days 2, 23. Methotrexate 1g/m2 days 15, 36 and 50.
Study NCT00193973 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Whole brain Irradiation, 30Gy in 20 fractions over 4 weeks
Study NCT03847194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Resilience in Stress Management (PRISM)
Description: PRISM was developed based on stress and coping theory to be a brief, disease non-specific, skills-based intervention targeting adolescent resilience resources. PRISM teaches 4 pillars of resilience including stress management, goal setting, cognitive restructuring and benefit-finding in a one-on-one training program consisting of two, 45-60 minute sessions and supported by 6-months of booster sessions and a fully developed digital app for practice and tracking. A family session follows the individual sessions and was designed for the adolescent to communicate to his/her caregiver(s) the skills learned, and how the caregiver(s) could best support ongoing practice.
Study NCT02720133 — intervention group
Intervention type: BIOLOGICAL
Intervention: biochemical parameters
Description: patients will be collected for analysis of blood standard examinations such as blood glucose, electrolytes (potassium, sodium, magnesium calcium), renal function and also the blood count, platelet aggregation.~All these tests should be practice before, during and after Ramadan fasting for comparison.
Study NCT03064243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: apatinib 500mg po. qd.
Study NCT01391845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulipristal acetate
Description: 30mg of ulipristal acetate orally the day of hCG injection in a unique dose